10-Q · May 11, 2026
Gain Therapeutics reported a net loss of $5.6 million for Q1 2026, up from a loss of $4.5 million in Q1 2025. The company continues to show no revenue generation, reflecting ongoing early-stage development challenges.…
Earnings analysis · 10-Q
GANX earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Q2 2026 diluted EPS of $(0.11) improved from $(0.13) in Q1 2026 and $(0.19) in the prior-year quarter, although the supplied 10-Q extract does not include revenue, margins, cash flow, balance-sheet, or segment data.…
Read full summary
Q2 2026 diluted EPS of $(0.11) improved from $(0.13) in Q1 2026 and $(0.19) in the prior-year quarter, although the supplied 10-Q extract does not include revenue, margins, cash flow, balance-sheet, or segment data. Disclosure controls were assessed as effective as of June 30, 2026, with no material changes in internal control reported. The principal newly disclosed negative is litigation seeking more than $3.1 million, with the motion to dismiss pending.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.11
What stood out
-
EPS improved year over year
Diluted EPS was $(0.11) in Q2 2026, improving from $(0.13) in Q1 2026 and $(0.19) in Q2 2025; the result also exceeded the $(0.15) consensus estimate.
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
What to watch
-
Pending litigation exceeds $3.1 million
The amended complaint seeks monetary damages in excess of $3.1 million, plus pre- and post-judgment interest. The defendants’ April 28, 2026 motion to dismiss is fully briefed and pending adjudication.
-
No updated risk-factor detail
The company states that its risk factors remain those described in the 10-K for the year ended December 31, 2025, filed March 26, 2026; no specific new or amended risk factor was identified in the supplied 10-Q text.
-
Controls have inherent limitations
The company acknowledges that its control systems provide only reasonable, rather than absolute, assurance and cannot ensure that errors, fraud, or all control issues will be detected.
Management's outlook
No quantitative financial guidance or MD&A outlook was provided in the supplied filing extract. Operational milestones cited in prior company disclosures include Phase 2 initiation for rexaceract expected in Q3 2026 and Phase 1b final results expected in Q4 2026.
Earlier filings 4
10-K · March 26, 2026
Gain Therapeutics’ 10-K emphasizes clinical progress for lead oral small molecule GT-02287 (Parkinson’s) and the company’s Magellan™ discovery platform as the core strategic moat. The filing documents positive Phase 1…
10-Q · November 12, 2025
Gain Therapeutics reported a Q3 2025 net loss per share of $0.15 (three months ended September 30, 2025), roughly in line with consensus and slightly improved versus Q3 2024 ($0.17). The company has $8.8 million of cash…
10-Q · August 12, 2025
Gain Therapeutics reported a narrower quarterly net loss of $5.81 million (EPS -$0.19) for the three months ended June 30, 2025 versus a loss of $8.14 million (EPS -$0.42) in the year-ago quarter, driven by lower R&D…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.